James Edgemond
2017
In 2017, James Edgemond earned a total compensation of $8.7M as Chief Financial Officer and Treasurer at United Therapeutics, a 111% increase compared to previous year.
Compensation breakdown
| Change in Pension Value and Nonqualified Deferred Compensation Earnings | $854,747 |
|---|---|
| Non-Equity Incentive Plan | $577,148 |
| Option Awards | $6,583,317 |
| Salary | $620,833 |
| Other | $17,000 |
| Total | $8,653,045 |
Edgemond received $6.6M in option awards, accounting for 76% of the total pay in 2017.
Edgemond also received $854.7K of change in pension value and nonqualified deferred compensation earnings, $577.1K in non-equity incentive plan, $620.8K in salary and $17K in other compensation.
Rankings
In 2017, James Edgemond's compensation ranked 826th out of 14,666 executives tracked by ExecPay. In other words, Edgemond earned more than 94.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 826 out of 14,666 | 94th |
Division Manufacturing | 277 out of 5,768 | 95th |
Major group Chemicals And Allied Products | 69 out of 2,074 | 97th |
Industry group Drugs | 49 out of 1,730 | 97th |
Industry Pharmaceutical Preparations | 40 out of 1,329 | 97th |
Source: SEC filing on April 27, 2018.
Edgemond's colleagues
We found three more compensation records of executives who worked with James Edgemond at United Therapeutics in 2017.